Bond Fund Claims Against Morgan Keegan Results in $3.6M in Awards

|

Two arbitration panels have ordered Morgan Keegan & Co. to pay a combined total of $3.6 million to two investors who lost money in the brokerage firm’s bond funds, which collapsed after the subprime mortgage crash in 2007.

The Financial Industry Regulatory Authority (FINRA) ruled in favor of the investors in two seperate bond fund arbitration claims filed against the company by Andrew Stein, of Jupiter, Florida, and General Henry Cobb, of Birmingham, Alabama. Cobb’s claim, which resulted in a $1.1 million award, was filed on behalf of three investment holding companies founded by the World War II Army veteran. Stein’s claim, which resulted in a $2.5 million award, was filed on behalf of the 38 year old investor and two of his companies.

Both arbitration claims involved similar allegations that Morgan Keegan was responsible for substantial losses in certain bond funds offered by the company as a result of negligence and failing to disclose the true amount of risk associated with the investments. The brokerage firm was also accused of artificially inflating the value of the funds’ assets to make them more stable.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The bond funds were heavily invested in the subprime mortgage market, and lost as much as 82% in value after the market imploded. The funds were subsequently taken from Morgan Keegan by its parent company, Regions Financial Corp., and transferred to Hyperion Brookfield Assed Management, Inc., which has since liquidated and closed down two of the funds.

Cobb sought $1.4 million in compensation for his losses and was awarded $1.1 million. Stein sought $12 million, and received $2.5 million. Stein’s award is the largest so far against Morgan Keegan over the bond funds, which has lost about a dozen cases and settled some others. FINRA, which oversees about 5,000 brokerage firms throughout the United States, did not provide an explanation for the rulings.

The decisions follow a September victory against Morgan Keegan by former National Basketball Association star Horace Grant, who was awarded $1.46 million for losses he suffered while invested in the funds. Morgan Keegan is appealing that decision.

Hundreds of other similar Morgan Keegan bond fund arbitration claims are currently pending against the brokerage firm. The cases involve several different Morgan Keegan funds, including the RMK Strategic Income Fund, RMK Select High Income Fund and RMK Advantage Fund. Some analysts speculate that Morgan Keegan bond fund awards may eventually exceed $200 million.

The Securities Exchange Commission (SEC) issued a “Wells Notice” last year to Morgan Keegan over the funds, an indication that it is considering criminal charges for violations of investment laws.


0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A new lawsuit against Roblox alleges that the platform’s inadequate safety measures enabled multiple sexual predators to exploit a five-year-old girl.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.